Trial reportDiabetes2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review.PloS one · 2025Pooled it
- ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.Hormone research in paediatrics · 2024Guideline
- Trial
- Trial
- Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.Diabetes, obesity & metabolism · 2022Trial
- Trial
- Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology · 2021Trial
- Trial
- Article
- Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial.Diabetologia · 2026Article
- Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile.Diabetes care · 2026Article
- A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.Diabetes, obesity & metabolism · 2026Article
- Unbiased discovery of autoreactive type 1 diabetes T-cell receptors that bind specific hybrid insulin peptides.Research square · 2026Article
- Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).Diabetes care · 2026Article
- Article
- New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026Review
- An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.Diabetes, obesity & metabolism · 2026Review
- Can we cure autoimmunity?Current opinion in immunology · 2026Review
- Modulating immune response for the prevention and treatment of type 1 diabetes.Frontiers in immunology · 2026Review
- Relevance of Quantitative Measures of Beta-Cell Function in Clinical Practice.Hormone research in paediatrics · 2026Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 11 institutions in 1 country.
Michael J HallerUniversity of Florida Diabetes Institute, Gainesville, FL hallemj@peds.ufl.edu.ORCID 0000-0002-2803-1824
S Alice LongBenaroya Research Institute, Seattle, WA.ORCID 0000-0002-0281-1240
J Lori BlanchfieldBenaroya Research Institute, Seattle, WA.
Desmond A SchatzUniversity of Florida Diabetes Institute, Gainesville, FL.ORCID 0000-0002-1044-5762
Jay S SkylerDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL.
Jeffrey P KrischerUniversity of South Florida, Tampa, FL.ORCID 0000-0003-4526-888X
Brian N BundyUniversity of South Florida, Tampa, FL.
Susan M GeyerUniversity of South Florida, Tampa, FL.
Megan V WarnockUniversity of South Florida, Tampa, FL.
Jessica L MillerUniversity of South Florida, Tampa, FL.
Mark A AtkinsonUniversity of Florida Diabetes Institute, Gainesville, FL.ORCID 0000-0001-8489-4782
Dorothy J BeckerDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL.
David A BaidalDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL.
Linda A DiMeglioIndiana University, Indianapolis, IN.
Stephen E GitelmanUniversity of California, San Francisco, San Francisco, CA.
Robin GolandColumbia University, New York, NY.
Peter A GottliebUniversity of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, CO.
Kevan C HeroldYale University, New Haven, CT.ORCID 0000-0003-1534-6613
Jennifer B MarksDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL.
Antoinette MoranUniversity of Minnesota, Minneapolis, MN.ORCID 0000-0002-2694-5147
Henry RodriguezUniversity of South Florida, Tampa, FL.
William E RussellVanderbilt University, Nashville, TN.
Darrell M WilsonStanford University, Stanford, CA.
Carla J GreenbaumBenaroya Research Institute, Seattle, WA.ORCID 0000-0003-4451-9800
Type 1 Diabetes TrialNet ATG-GCSF Study Group
University of South Florida · USUniversity of Miami · USBenaroya Research InstituteUniversity of Florida · USColumbia University · USIndiana University – Purdue University Indianapolis · USStanford University · USUniversity of California, San Francisco · USUniversity of Minnesota · USVanderbilt University · USYale University · US
Funding
Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6MVanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MUniversity of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3MClinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MData Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3UC4DK117009 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2017 to 2019
$49.6MColorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0MNIDDK Type 1 Diabetes TrialNet Data Coordinating CenterUC4DK097835 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2012 to 2012
$45.0MStanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0MVector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUsing social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MNCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR001427NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR001872NCATS NIH HHS UL1 TR002243NCATS NIH HHS UL1 TR002529NCATS NIH HHS UL1 TR003142NIAID NIH HHS P01 AI042288NIAID NIH HHS UM1 AI109565NIDDK NIH HHS P30 DK017047NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103266NIDDK NIH HHS U01 DK103282NIDDK NIH HHS U01 DK106984NIDDK NIH HHS U01 DK107014NIDDK NIH HHS UC4 DK097835NIDDK NIH HHS UC4 DK106993NIDDK NIH HHS UC4 DK117009
Abstract
A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA
Indexed as
AdolescentAdultAntilymphocyte SerumCD4-CD8 RatioChildC-PeptideDiabetes Mellitus, Type 1Double-Blind MethodFemaleFlow CytometryGlycated HemoglobinGranulocyte Colony-Stimulating FactorHumansImmunologic FactorsMaleT-Lymphocytes, RegulatoryAntilymphocyte SerumC-PeptideGlycated HemoglobinGranulocyte Colony-Stimulating Factorhemoglobin A1c protein, humanImmunologic Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.